Showing 821 - 840 results of 872 for search '"preclinical"', query time: 0.08s Refine Results
  1. 821

    Should we consider microbiota-based interventions as a novel therapeutic strategy for schizophrenia? A systematic review and meta-analysis by Lucas Hassib, Alexandre Kanashiro, João Francisco Cordeiro Pedrazzi, Bárbara Ferreira Vercesi, Sayuri Higa, Íris Arruda, Yago Soares, Adriana de Jesus de Souza, Alceu Afonso Jordão, Francisco Silveira Guimarães, Frederico Rogério Ferreira

    Published 2025-02-01
    “…This review also discusses clinical and preclinical studies to elucidate the neural, immune, and metabolic pathways by which microbiota manipulation, particularly with Lactobacillus and Bifidobacterium genera, may exert beneficial effects on schizophrenia symptoms via the gut-brain axis. …”
    Get full text
    Article
  2. 822

    Exploring the benefits and prescribing informations of combining East Asian herbal medicine with conventional medicine in the treatment of rheumatoid arthritis: A systematic review... by Hee-Geun Jo, Jihye Seo, Eunhye Baek, Donghun Lee

    Published 2025-02-01
    “…Through a comprehensive analysis of a polyherbal prescription dataset, we identified 18 key herbs and 16 significant combination rules, further supported by relevant preclinical evidence. These herbs and synergistic herbal combinations were anticipated to be the most pharmacologically influential in contributing to the meta-analysis outcomes, as substantiated by analytical metrics including network topology and intricate association pattern evaluations. …”
    Get full text
    Article
  3. 823

    Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9 by Tao Fan, Chu Xiao, Ziqin Deng, Shuofeng Li, He Tian, Yujia Zheng, Bo Zheng, Chunxiang Li, Jie He

    Published 2025-01-01
    “…This study provided a new H3K4me3-associated biomarker system to predict tumor immunotherapy response and suggested the preclinical rationale for investigating the roles of SLAMF9 in cancer immunity regulation and treatment.…”
    Get full text
    Article
  4. 824
  5. 825

    The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial by Elena Giudice, Tzu-Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome, Marc R. Radke, Elizabeth M. Swisher, Stanley Lipkowitz, Kristen Ibanez, Duncan Donohue, Tyler Malys, Min-Jung Lee, Bernadette Redd, Elliot Levy, Shraddha Rastogi, Nahoko Sato, Jane B. Trepel, Jung-Min Lee

    Published 2024-03-01
    “…Transcriptomic analysis revealed high levels of DNA replication-related genes (POLA1, POLE, GINS3) associated with lack of clinical benefit [defined post-hoc as PFS < 6 months]. Subsequent preclinical experiments demonstrated significant cytotoxicity of POLA1 silencing in combination with CHK1i in platinum-resistant HGSOC cell line models. …”
    Get full text
    Article
  6. 826

    Bone marrow mesenchymal stem cell-derived extracellular vesicles alleviate diabetes-exacerbated atherosclerosis via AMPK/mTOR pathway-mediated autophagy-related macrophage polariza... by Libo Liu, Ziyu An, Huan Zhang, Xueqi Wan, Xin Zhao, Xueyao Yang, Jinfan Tian, Xiantao Song

    Published 2025-01-01
    “…Abstract Introduction Bone marrow-derived mesenchymal stem cell-derived extracellular vesicles (BMSC-EVs) are widely used for therapeutic purposes in preclinical studies. However, their utility in treating diabetes-associated atherosclerosis remains largely unexplored. …”
    Get full text
    Article
  7. 827

    The association of visceral and subcutaneous fat areas with phenotypic age in non-elderly adults, mediated by HOMA-IR and HDL-C by Yuanhong Liu, Min Xu, Liqing Wang, Linyun Meng, Mengran Li, Shumin Mu

    Published 2025-01-01
    “…The epigenetic clock ‘Phenotypic Age’ (PhenoAge) represents ‘preclinical ageing’. Phenotypic Age Acceleration (PhenoAgeAccel) is defined as the residual from a linear regression model predicting PhenoAge on the basis of chronological age. …”
    Get full text
    Article
  8. 828

    Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat by Tamara Zenz, Robert Jenke, Denys Oliinyk, Sandra Noske, René Thieme, Tim Kahl, Ines Gockel, Florian Meier-Rosar, Achim Aigner, Thomas RH Büch

    Published 2025-02-01
    “…Introduction: Histone deacetylase inhibitors (HDACi) have shown promising preclinical activity in gastric cancer cells; unfortunately, however, these could not be confirmed in clinical trials. …”
    Get full text
    Article
  9. 829

    B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells by Kun Wang, Gianpietro Dotti, Soldano Ferrone, Yufeng Wang, Yin P Hung, Tao Ma, Giulia Cattaneo, Xinhui Wang, David O Osei-Hwedieh, Tara A Walhart, Joseph H Schwab

    Published 2025-01-01
    “…These results provide preclinical evidence for further developing this combinatorial RT and B7-H3 CAR-T cell therapy model in chordoma…”
    Get full text
    Article
  10. 830

    Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites by Thomas Kayser, MD, BS, Ronald Smulders, MD, PhD, Tomohiro Kusawake, PhD, Erik Wambre, PhD, Gurunadh R. Chichili, PhD, Mary B. Blauwet, DrPH, Anna Spence, MS, Melanie Patton, BS, Rima Tabash, PhD, Hannah A. DeBerg, PhD, Sugandhika Khosa, MS, Philipp Badorrek, MD, Jens M. Hohlfeld, MD, Brian C. Ferslew, PharmD, PhD

    Published 2025-05-01
    “…The novel LAMP (lysosomal-associated membrane protein)-based DNA vaccine ASP2390 targets major HDM allergens, potentially shifting immune responses toward nonallergic pathways and minimizing the risk of atopy, with positive safety and efficacy signals in preclinical models. Objective: We evaluated the safety, tolerability, and efficacy of first-in-human intradermal ASP2390 in adults with HDM allergy. …”
    Get full text
    Article
  11. 831

    A first evaluation of the efficacy of minibeam radiation therapy combined with an immune check point inhibitor in a model of glioma-bearing rats by Lorea Iturri, Emmanuel Jouglar, Cristèle Gilbert, Julie Espenon, Marjorie Juchaux, Yolanda Prezado

    Published 2025-03-01
    “…One example is minibeam radiation therapy (MBRT). Preclinical experiments have shown that MBRT leads to a remarkable widening of the therapeutic window for GBM and elicits an effective immune priming. …”
    Get full text
    Article
  12. 832

    Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production by Heather J Bax, Jitesh Chauhan, Alexandra J McCraw, Melanie Grandits, Chara Stavraka, Heike Lentfer, Tim Hillyer, Simon Carroll, Kim Vigor, Chris Selkirk, Mariangela Figini, Jack Cheeseman, Paulina A Urbanowicz, Richard A Gardner, Daniel I R Spencer, Nigel Westwood, Sarah Mellor, James Spicer, Debra H Josephs, Sophia N Karagiannis

    Published 2025-12-01
    “…Antibodies used for cancer therapy are monoclonal IgGs, but tumor-targeting IgE antibodies have shown enhanced effector cell potency against cancer in preclinical models. Research-grade recombinant IgE antibodies have been generated and studied for several decades. …”
    Get full text
    Article
  13. 833
  14. 834
  15. 835

    Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model by Atteneri López-Arencibia, Carlos J. Bethencourt-Estrella, Desirée San Nicolás-Hernández, Rubén L. Rodríguez-Expósito, Angélica Domínguez-de-Barros, Lizbeth Salazar-Villatoro, Maritza Omaña-Molina, Francisco Cen-Pacheco, Ana R. Díaz-Marrero, José J. Fernández, Elizabeth Córdoba-Lanús, Jacob Lorenzo-Morales, José E. Piñero

    Published 2024-12-01
    “…One of the most important steps in preclinical drug discovery is to demonstrate the in vivo efficacy of potential leishmanicidal compounds and good characteristics at the level of parasite killing prior to initiating human clinical trials. …”
    Get full text
    Article
  16. 836

    An automated platform for simultaneous, longitudinal analysis of engineered neuromuscular tissues for applications in neurotoxin potency testing by Jacob W. Fleming, Molly C. McCloskey, Kevin Gray, David R. Nash, Vincent Leung, Christos Michas, Shawn M. Luttrell, Christopher Cavanaugh, Julie Mathieu, Shawn Mcquire, Mark Bothwell, David L. Mack, Nicholas A. Geisse, Alec S.T. Smith

    Published 2025-01-01
    “…Challenges with scarcity, scalability, throughput, and ethical considerations further limit the suitability of animal models for preclinical screening. Engineered models have emerged as alternatives for studying NMJ functionality in response to genetic and/or pharmacological challenge. …”
    Get full text
    Article
  17. 837

    The factors impacting on Gleason score upgrading in prostate cancer with initial low Gleason scores by Tzu-Heng Huang, Wei-Ming Li, Hung-Lung Ke, Ching-Chia Li, Wen-Jeng Wu, Hsin-Chih Yeh, Yen-Chun Wang, Hsiang-Ying Lee

    Published 2025-02-01
    “…To further explore preclinical variables, a cut-off value for PV (≤ 38 ml, p value = 0.0017) and PSAD (≥ 0.26 ng/ml2, p value = 0.0013) were identified to be associated with GS upgrading. …”
    Get full text
    Article
  18. 838
  19. 839

    Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors by Laetitia Fend, Eric Quemeneur, Monika Semmrich, Jean-Baptiste Marchand, Matilda Rehn, Nathalie Silvestre, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Björn Frendeus, Petra Holmkvist, Carolin Svensson, Christelle Remy, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén

    Published 2022-01-01
    “…At a mechanistic level, accumulating preclinical and clinical data indicate dual mechanisms for αCTLA-4; ICB and regulatory T cell (Treg) depletion are both thought to contribute efficacy and toxicity in available, systemic, αCTLA-4 regimens. …”
    Get full text
    Article
  20. 840

    Ibuprofen reduces inflammation, necroptosis and protects photoreceptors from light-induced retinal degeneration by Ping-Wu Zhang, Zi-He Wan, Weifeng Li, Abhishek Vats, Kunal Mehta, Laura Fan, Lingli Zhou, Sean Li, Gloria Li, Casey J. Keuthan, Cynthia Berlinicke, Cheng Qian, Noriko Esumi, Elia J Duh, Donald J. Zack

    Published 2025-01-01
    “…Unfortunately, current treatments for these diseases are limited at best. Genetic and other preclinical evidence suggest a relationship between retinal degeneration and inflammation. …”
    Get full text
    Article